Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LabVax 3(22)-23 and GM-CSF +/- Pembrolizumab in Advanced Adenocarcinoma
NCT05101356Phase 2Suspended
- Sponsor
- University of California, Davis
- Start
- Jan 2021
- Primary completion
- Dec 2030
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LabVax 3(22)-23 in Adenocarcinoma, sponsored by University of California, Davis. Started Jan 2021; status: suspended.
02
Drugs
LabVax 3(22)-23
03
Conditions
Adenocarcinoma
Beyond the preview
Go deeper on NCT05101356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101356.